The Association of Serum Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Thymidine Kinase, and Tissue Polypeptide Specific Antigen with Outcomes of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab: a Retrospective Study

详细信息    查看全文

• 作者：Ondrej Fiala ; Jindrich Finek ; Tomas Buchler ; Vit Martin Matejka…
• 刊名：Targeted Oncology
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：10
• 期：4
• 页码：549-555
• 全文大小：350 KB
• 参考文献：1.Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-0CrossRef PubMed
  2.Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765-1CrossRef PubMed
  3.Yamashita K, Watanabe M (2009) Clinical significance of tumor markers and an emerging perspective on colorectal cancer. Cancer Sci 100:195-CrossRef PubMed
  4.Duffy MJ, Lamerz R, Haglund C, Nicolini A, Kalousová M, Holubec L et al (2014) Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer 134:2513-2PubMedCentral CrossRef PubMed
  5.Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP (1989) Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 57:327-4CrossRef PubMed
  6.Screaton RA, Penn LZ, Stanners CP (1997) Carcinoembryonic antigen, a human tumor marker, cooperates with Myc and Bcl-2 in cellular transformation. J Cell Biol 137:939-2PubMedCentral CrossRef PubMed
  7.Bramswig KH, Poettler M, Unseld M, Wrba F, Uhrin P, Zimmermann W et al (2013) Soluble carcinoembryonic antigen activates endothelial cells and tumor angiogenesis. Cancer Res 73:6584-6CrossRef PubMed
  8.Ballehaninna UK, Chamberlain RS (2012) The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol 3:105-9PubMedCentral PubMed
  9.Zhou J, He E, Skog S (2013) The proliferation marker thymidine kinase 1 in clinical use. Mol Clin Oncol 1:18-8PubMedCentral PubMed
  10.Rydlander L, Ziegler E, Bergman T, Sch?berl E, Steiner G, Bergman AC et al (1996) Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. Eur J Biochem 241:309-4CrossRef PubMed
  11.Bodenmuller H (1995) The biochemistry of CYFRA 21-1 and other cytokeratin tests. Scand J Clin Lab Investig Suppl 221:60-CrossRef
  12.Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumours. European organization for research and treatment of cancer, national cancer institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 3:205-6CrossRef
  13.Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al (2004) Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 250:2335-2CrossRef
  14.Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S (2005) Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival in patients with metastatic colorectal cancer. J Clin Oncol 23:3706-2CrossRef PubMed
  15.Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013-CrossRef PubMed
  16.Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM et al (2009) Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 14:862-0CrossRef PubMed
  17.Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M et al (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20:1842-CrossRef PubMed
  18.Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky TC et al (2010) Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer 103:1407-4PubMedCentral CrossRef PubMed
  19.Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ (2013) Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 31:1219-0CrossRef PubMed
  20.Zhang W, Azuma M, Lurje G, Gordon MA, Yang D, Pohl A et al (2010) Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). Anticancer Res 30:4209-7PubMed
  21.Huh JW, Oh BR, Kim HR, Kim YJ (2010) Preoperative carcinoembryonic antigen level as an independent prognostic factor in potentially curative colon cancer. J Surg Oncol 101:396-00PubMed
  22.Sun LC, Chu KS, Cheng SC, Lu CY, Kuo CH, Hsieh JS et al (2009) Preoperative serum carcinoembryonic antigen, albumin and age are supplementary to UICC staging systems in predicting survival for colorectal cancer patients undergoing surgical treatment. BMC Cancer 9:288PubMedCentral CrossRef PubMed
  23.Park IJ, Choi GS, Lim KH,
• 作者单位：Ondrej Fiala (1) (2)
  Jindrich Finek (1)
  Tomas Buchler (3)
  Vit Martin Matejka (1)
  Lubos Holubec (1) (2)
  Jana Kulhankova (1)
  Zbynek Bortlicek (4)
  Vaclav Liska (2) (5)
  Ondrej Topolcan (6)
  
  1. Department of Oncology and Radiotherapy, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, alej Svobody 80, 304 60, Pilsen, Czech Republic
  2. Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic
  3. Department of Oncology and First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic
  4. Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
  5. Department of Surgery, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Pilsen, Czech Republic
  6. Department of Nuclear Medicine, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Pilsen, Czech Republic
  
• 刊物主题：Oncology; Biomedicine general;
• 出版者：Springer Paris
• ISSN：1776-260X

文摘

The aim of our retrospective study was to analyze the association of selected tumor markers (TMs) including serum carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA 19-9), thymidine kinase, and tissue polypeptide specific antigen with outcomes in patients with metastatic colorectal cancer (mCRC) treated with bevacizumab. There is an increasing body of evidence from retrospective/observational studies that some serum TMs may be predictive of effect of targeted therapies in mCRC. In our study, the cohort included 152 patients treated with bevacizumab-based therapy between years 2005 and 2014 at Department of Oncology and Radiotherapy, Medical School and Teaching Hospital Pilsen. Serum samples for measurement of TMs were collected within 1 month before the initiation of bevacizumab-based treatment. In multivariate Cox analysis that included serum tumor markers and clinical baseline parameters, the number of metastatic sites (hazard ratio [HR]--.00, p--.001) and CEA levels (HR--.80, p-lt;-.001) were significantly associated with progression-free survival, whereas CA 19-9 levels (HR--.25, p--.008) were the only studied parameter associated with overall survival. Quantification of serum CEA and CA 19-9 is simple and readily available, and their candidate prognostic importance in the setting of antiangiogenesis therapy deserves to be studied in prospective trials.